Format

Send to

Choose Destination
Expert Rev Anti Infect Ther. 2008 Oct;6(5):657-69. doi: 10.1586/14787210.6.5.657.

Multiresistant Enterobacteriaceae: new threat of an old problem.

Author information

1
Department of Pathology and Laboratory Medicine, Microbiology and Infectious Diseases, University of Calgary, Division of Microbiology, Calgary Laboratory Services, Calgary, Alberta, Canada. johann.pitout@cls.ab.ca

Abstract

The Enterobacteriaceae are among the most important causes of serious nosocomial and community-onset bacterial infections in humans, and resistance to antimicrobial agents in these species has become an increasingly relevant problem for healthcare providers. beta-lactam and fluoroquinolone antibiotics are important drug classes used to treat infections caused by Enterobacteriaceae. Emerging resistance mechanisms against these agents have recently been described in Enterobacteriaceae and include the production of newer beta-lactamases and plasmid-mediated quinolone resistance. The newer beta-lactamases consist of the following: plasmid-mediated AmpC beta-lactamases (e.g., ephamycin [CMY], CMY types), extended-spectrum beta-lactamases (e.g., cefotaxime [CTX], CTX-M first isolated at Munich) and carbapenem-hydrolyzing enzymes (e.g., Klebsiella pneumoniae carbapenemase [KPC], KPC types and the metallo-beta-lactamases). Recent developments in the epidemiology, clinical relevance and laboratory detection of infections caused by multiresistant Enterobacteriaceae with these new types of resistance mechanisms will be addressed in this review.

PMID:
18847404
DOI:
10.1586/14787210.6.5.657
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center